Equities research analysts expect that Fate Therapeutics Inc (NASDAQ:FATE) will announce earnings per share of ($0.26) for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Fate Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.24) and the lowest estimate coming in at ($0.27). Fate Therapeutics reported earnings per share of ($0.21) during the same quarter last year, which indicates a negative year-over-year growth rate of 23.8%. The firm is expected to report its next earnings report on Thursday, March 15th.
On average, analysts expect that Fate Therapeutics will report full year earnings of ($0.99) per share for the current fiscal year, with EPS estimates ranging from ($1.00) to ($0.97). For the next financial year, analysts forecast that the firm will post earnings of ($0.91) per share, with EPS estimates ranging from ($1.06) to ($0.72). Zacks’ EPS averages are an average based on a survey of analysts that cover Fate Therapeutics.
Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). Fate Therapeutics had a negative return on equity of 64.55% and a negative net margin of 935.09%. The company had revenue of $1.03 million for the quarter, compared to analyst estimates of $0.95 million. The company’s revenue for the quarter was up .0% on a year-over-year basis.
In other news, General Counsel Cindy Tahl sold 8,091 shares of the stock in a transaction on Monday, October 16th. The stock was sold at an average price of $3.85, for a total transaction of $31,150.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Daniel D. Shoemaker sold 13,225 shares of the stock in a transaction on Monday, October 16th. The shares were sold at an average price of $3.87, for a total value of $51,180.75. The disclosure for this sale can be found here. Company insiders own 10.88% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. New York State Common Retirement Fund purchased a new stake in shares of Fate Therapeutics in the second quarter valued at $131,000. Rhumbline Advisers purchased a new stake in shares of Fate Therapeutics during the second quarter worth $133,000. Hochman Cole Investment Advisors Inc. purchased a new stake in shares of Fate Therapeutics during the third quarter worth $158,000. Schwab Charles Investment Management Inc. purchased a new stake in shares of Fate Therapeutics during the second quarter worth $214,000. Finally, California State Teachers Retirement System purchased a new stake in shares of Fate Therapeutics during the second quarter worth $219,000. Institutional investors own 60.97% of the company’s stock.
Fate Therapeutics (NASDAQ FATE) opened at $5.61 on Friday. Fate Therapeutics has a fifty-two week low of $2.40 and a fifty-two week high of $5.87. The stock has a market capitalization of $258.76, a P/E ratio of -5.91 and a beta of 1.51. The company has a debt-to-equity ratio of 0.32, a current ratio of 7.21 and a quick ratio of 7.21.
ILLEGAL ACTIVITY WARNING: This story was first posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.com-unik.info/2017/12/24/brokerages-anticipate-fate-therapeutics-inc-fate-to-post-0-26-earnings-per-share.html.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.